Loading...
XNAS
CRDF
Market cap142mUSD
Dec 05, Last price  
2.11USD
1D
-2.31%
1Q
-2.76%
Jan 2017
-91.63%
IPO
-90.62%
Name

Cardiff Oncology Inc

Chart & Performance

D1W1MN
XNAS:CRDF chart
P/E
—
P/S
207.98
EPS
—
Div Yield, %
—
Shrs. gr., 5y
51.48%
Rev. gr., 5y
22.76%
Revenues
683k
+39.96%
00650,000265,665257,696450,000259,246280,000313,000381,000505,000378,000245,000365,993359,000386,000488,000683,000
Net income
-45m
L+9.63%
-5,371,027-7,844,326-2,480,000-5,449,138-2,239,212-11,566,000-11,810,938-14,325,000-27,471,000-39,204,000-24,907,000-16,461,000-16,152,000-19,279,947-27,742,000-37,506,000-41,441,000-45,431,000
CFO
-38m
L+22.04%
0-4,399,446-1,230,000-2,088,716-1,930,301-4,934,661-7,317,248-12,727,385-22,119,025-31,040,000-23,281,000-13,200,000-13,268,000-16,314,962-23,040,000-33,820,000-30,887,000-37,693,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
URL
https://cardiffoncology.com/
IPO date
Jul 27, 2004
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT